Browse FAM83B

Summary
SymbolFAM83B
Namefamily with sequence similarity 83, member B
Aliases FLJ30642; C6orf143; chromosome 6 open reading frame 143; Protein FAM83B
Chromosomal Location6p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Membrane
Domain PF07894 Protein of unknown function (DUF1669)
Function

Probable proto-oncogene that functions in the epidermal growth factor receptor/EGFR signaling pathway. May activate both the EGFR itself and downstream RAS/MAPK and PI3K/AKT/TOR signaling cascades.

> Gene Ontology
 
Biological Process GO:0007173 epidermal growth factor receptor signaling pathway
GO:0038127 ERBB signaling pathway
Molecular Function GO:0005154 epidermal growth factor receptor binding
GO:0036312 phosphatidylinositol 3-kinase regulatory subunit binding
GO:0036313 phosphatidylinositol 3-kinase catalytic subunit binding
GO:0043548 phosphatidylinositol 3-kinase binding
GO:0070851 growth factor receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFAM83B
Namefamily with sequence similarity 83, member B
Aliases FLJ30642; C6orf143; chromosome 6 open reading frame 143; Protein FAM83B
Chromosomal Location6p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FAM83B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFAM83B
Namefamily with sequence similarity 83, member B
Aliases FLJ30642; C6orf143; chromosome 6 open reading frame 143; Protein FAM83B
Chromosomal Location6p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FAM83B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFAM83B
Namefamily with sequence similarity 83, member B
Aliases FLJ30642; C6orf143; chromosome 6 open reading frame 143; Protein FAM83B
Chromosomal Location6p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FAM83B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5120.22
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0720.92
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.9480.144
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1250.794
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0440.98
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3410.874
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4870.633
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2870.861
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6610.712
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5970.398
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.5970.536
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0160.937
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FAM83B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141728.6028.60.0318
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103400400.497
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277340.716.424.30.0157
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275940.716.923.80.0289
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211728.623.55.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)862516.78.31
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.827.33.51
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.53.76.80.393
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolFAM83B
Namefamily with sequence similarity 83, member B
Aliases FLJ30642; C6orf143; chromosome 6 open reading frame 143; Protein FAM83B
Chromosomal Location6p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FAM83B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFAM83B
Namefamily with sequence similarity 83, member B
Aliases FLJ30642; C6orf143; chromosome 6 open reading frame 143; Protein FAM83B
Chromosomal Location6p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FAM83B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FAM83B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFAM83B
Namefamily with sequence similarity 83, member B
Aliases FLJ30642; C6orf143; chromosome 6 open reading frame 143; Protein FAM83B
Chromosomal Location6p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FAM83B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFAM83B
Namefamily with sequence similarity 83, member B
Aliases FLJ30642; C6orf143; chromosome 6 open reading frame 143; Protein FAM83B
Chromosomal Location6p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FAM83B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFAM83B
Namefamily with sequence similarity 83, member B
Aliases FLJ30642; C6orf143; chromosome 6 open reading frame 143; Protein FAM83B
Chromosomal Location6p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FAM83B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFAM83B
Namefamily with sequence similarity 83, member B
Aliases FLJ30642; C6orf143; chromosome 6 open reading frame 143; Protein FAM83B
Chromosomal Location6p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FAM83B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.